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Clinical review
Science, medicine, and the future
Omega 3 fatty acids and cardiovascular disease—fishing
for a natural treatment
Jehangir N Din, David E Newby, Andrew D Flapan
Omega 3 fatty acids from fish and fish oils can protect against coronary heart disease. This article
reviews the evidence regarding fish oils and coronary disease and outlines the mechanisms through
which fish oils might confer cardiac benefits
Omega 3 fatty acids from fish and fish oils can protect
against coronary heart disease. Both health profession-
als and the public are increasingly interested in their
role in the prevention and management of coronary
heart disease. In this era of multiple pharmacological
treatments for cardiovascular disease many believe that
simple dietary interventions or nutritional supple-
ments may be a more natural and acceptable method
of providing benefits.
Several areas of uncertainty remain. The optimal
intake of omega 3 fatty acids is not firmly established,
nor is their mechanism of action fully understood.
Some studies have produced conflicting results, and
concerns have been increasing about environmental
contamination of certain fish. This article reviews the
current evidence regarding fish oils and cardiovascular
disease, their possible mechanism of action, and
potential future developments and research strategies.
Sources and selection criteria
We searched PubMed for relevant articles by using the
key words “fish,” “fish oils,” “omega 3 fatty acids,” and
“cardiovascular disease.” References identified in the
search are on bmj.com
Omega 3 polyunsaturated fatty acids
The association between omega 3 fatty acids and
cardiovascular disease was established following the
observation that the Greenland Inuit had low mortality
from coronary heart disease despite a diet that is rich
in fat. In the 1970s the Danish investigators Bang and
Dyerberg proposed that this could be because of the
high content of omega 3 fatty acid in the Inuit diet,1
which consisted largely of fish, seal, and whale (fig 1).
Additional references (w1-w15) are on bmj.com
Fig 1 Greenland Inuit gutting a seal in the early 1900s. Their diet
consisted largely of fish, whale, seal, and walrus, resulting in a high
intake of omega 3 fatty acids. Copyright Arctic Institute, used with
permission from Leif Vanggaard, Arctic Institute
Summary points
Coronary heart disease is still the most common
cause of death in the United Kingdom
Omega 3 fatty acids from fish and fish oils can
protect against coronary heart disease
There is evidence to support the use of fish or fish
oil supplements after myocardial infarction
The mechanisms by which fish oils confer their
benefits are not fully understood
Unravelling these mechanisms may identify novel
therapeutic targets and could help guide the
development of future treatments for coronary
heart disease
Future trials may identify other patients who
could benefit, such as those with stable angina,
risk factors for coronary heart disease, or left
ventricular dysfunction
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Omega 3 fatty acids, along with omega 6 fatty acids,
are essential polyunsaturated fatty acids (fig 2 and fig
3). The Western diet is abundant in omega 6 fatty acids,
mainly from vegetable oils rich in linoleic acid.2
However, humans lack the necessary enzymes to
convert omega 6 fatty acids to omega 3 fatty acids, and
the latter must be obtained from separate dietary
sources. While  linolenic acid (ALA) is available from
certain plants, eicosapentanoic acid (EPA) and docosa-
hexanoic acid (DHA) are derived from fish and fish
oils. This review is limited to the two marine derived
omega 3 fatty acids.
Epidemiological and observational
studies
Most studies have shown an inverse association
between fish consumption and the risk of coronary
heart disease.3–5 Furthermore, both consumption of
fish6 and higher blood concentrations of omega 3 fatty
acids7 are associated with a reduced risk of sudden
death. However, some studies8 w1 have not found a rela-
tion between intake of fish and coronary heart disease.
These inconsistencies could be due to differences in
methods, study populations, or fish. Importantly, most
studies showing no association were in populations
with an already moderate fish intake, potentially mask-
ing any relation. Overall, fish consumption seems to be
beneficial, and a systematic review of 11 prospective
cohort studies concluded that fish intake notably
reduced mortality due to coronary heart disease in
populations at increased risk.9
Clinical intervention trials
Several trials have assessed the effects of fish and fish
oil supplements on coronary heart disease, mainly
after myocardial infarction (table 1). The diet and rein-
farction trial (DART) randomised 2033 men with a
recent myocardial infarction to three dietary interven-
tions.10 Patients who received advice on fish had a rela-
tive reduction in total mortality of 29% during the two
year follow up (P < 0.05), mainly because of a reduction
in deaths from coronary heart disease. The open label
Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico Prevenzione (GISSI-
Prevenzione) trial randomised 11 324 patients after
myocardial infarction to either a daily capsule of about
850 mg omega 3 fatty acid, 300 mg vitamin E, both, or
neither.11 After 3.5 years participants randomised to
fish oil capsules had a reduction in relative risk of 15%
in the composite primary end point of total mortality,
non-fatal myocardial infarction, and stroke (P = 0.023).
The relative risk of cardiovascular death was also
reduced, by 30% (P = 0.024), and of sudden death by
45% (P = 0.01). These benefits were apparent within
just four months of randomisation.w2
Two smaller secondary prevention trials have also
assessed the effects of omega 3 fatty acids. In an Asian
population patients with a suspected myocardial
infarction randomised to fish oil capsules experienced
a significant reduction in mortality from coronary
heart disease after one year compared with placebo.12
However, a Norwegian study reported no benefit in
patients after myocardial infarction who were given
fish oil capsules compared with placebo after 1.5
years.13 This may have been because of the high
habitual fish consumption among the general popula-
tion in that area, with omega 3 supplementation
conferring no additional benefit.
A recent trial of 3114 men with angina unexpect-
edly found that individuals advised to eat oily fish, and
particularly those given fish oil capsules, had a higher
risk of cardiac death than people not given advice to
eat fish (11.5% v 9%, P = 0.02).14 The investigators
speculated that this may have arisen from risk
compensation or other changes in patients’ behaviour.
Several flaws in this study weakened the validity of the
results, and they should be viewed with caution until
more evidence becomes available.
Fats and fatty acids
Unsaturated fats
Saturated fats
Animal fats, butter, lard
Polyunsaturated fats Monounsaturated fats
Omega 3 fatty acids
Eicosapentanoic acid:
fish, shellfish
Docosahexanoic acid:
fish, shellfish
α linolenic acid:
flaxseed, soybean,
walnut, rapeseed oils
Omega 6 fatty acids
Corn oil
Safflower oil
Sunflower oil
Omega 9 fatty acids
Olive oil
Avocados
Peanuts
Almonds
Fig 2 Fatty acids are saturated, monounsaturated, or
polyunsaturated. Two types of polyunsaturated fatty acid exist—the
omega 6 and the omega 3 fatty acids. The omega 6 fatty acids are
available mainly from vegetable oils. Three types of omega 3 fatty
acid exist:  linolenic acid is available from certain plants but
eicosapentanoic acid and docosahexanoic acid must be obtained
from marine sources
Omega 6 fatty acids
CH3
CH3
CH3
CH3
COOH COOH
COOH
COOH
C18:2n-6
Linoleic acid
C20:4n-6
Arachidonic acid
C22:5n-6
Docosapentanoic acid
C18:3n-3
α linolenic acid 
C20:5n-3
Eicosapentanoic acid
(EPA)
C22:6n-3
Docosahexanoic acid
COOH
COOH
CH3
CH3
Omega 3 fatty acids
Plant derived
Marine derived
Fig 3 Structures of the two classes of polyunsaturated fatty acids. The omega 3 fatty acids
have their first double bond at the third carbon molecule from the methyl (CH3) end of the
fatty acid, whereas the omega 6 fatty acids have their first double bond at the sixth carbon
molecule. The chemical names for each fatty acid are also given: the number of carbon atoms
is given first, followed by the number of double bonds and the position of the first double
bond. Omega 6 linoleic acid can be desaturated in certain plants to form omega 3  linolenic
acid. Whereas linoleic acid is mainly converted into arachidonic acid,  linolenic is elongated
and desaturated into eicosapentanoic acid and then docosahexanoic acid
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Mechanism of action
Although the weight of evidence outlined above
supports a protective effect of omega 3 fatty acids on
coronary heart disease, the mechanisms through
which they confer these benefits remain unclear.
Omega 3 fatty acids have several potentially cardiopro-
tective effects (box 1), although the relative contribu-
tion of each of these is not fully understood.
Arrhythmias
The benefits of fish oils were originally thought to be
due to their antithrombotic effects, but recent evidence
has indicated that the predominant effect may be
antiarrhythmic. In the GISSI-Prevenzione trial the
decrease in mortality was largely due to a reduction in
sudden death,11 and, as in DART,10 no reduction in the
rate of non-fatal myocardial infarction occurred. Fish
oil supplementation increases heart rate variability in
patients after myocardial infarction, which correlates
with a lower risk of mortality and malignant
arrhythmia.15 In animal models fish oil protects against
ventricular fibrillation after surgical occlusion of a cor-
onary artery.16 The addition of eicosapentanoic acid or
docosahexanoic acid can prevent or terminate
pharmacologically induced arrhythmias in cultured
cardiomyocytes from newborn rats.16 However, studies
are necessary to show a direct antiarrhythmic effect in
humans and trials are currently under way in patients
with implantable defibrillators.
Thrombosis
Activation of platelets and their deposition at sites of
unstable plaque rupture promotes thrombus formation,
and these critical events have become a common thera-
peutic target in acute coronary syndromes.However, the
effects of omega 3 fatty acids on platelet function and
thrombosis are controversial. Large doses reduce plate-
let aggregation, but smaller amounts have modest plate-
let inhibitory effects.17 Omega 3 fatty acids have
inconsistent effects on fibrinolysis and little effect on
blood coagulability.18 Therefore, although omega 3 fatty
acids have an antithrombotic effect, its relevance to the
mortality reduction seen with lower doses is unclear.
Atherosclerosis
Omega 3 fatty acids may also influence the atheroscle-
rotic process. Fish oil fed to experimental animals pro-
tects against progression of atherosclerotic plaques.w3 w4
In humans with coronary heart disease omega 3 fatty
acid supplementation versus placebo for two years
resulted in modest improvements in atherosclerosis as
assessed by angiography.w5 These effects may be due to
a reduction in lipids, inflammation, production of
growth factor, or suppression of smooth muscle cell
proliferation.w6 An important recent study randomised
patients awaiting carotid endarterectomy to fish oil
capsules, sunflower oil capsules, or control until
surgery and then assessed morphology of the plaque.19
Omega 3 fatty acids were readily incorporated into
atherosclerotic plaques in the fish oil group, and these
plaques were more likely to have thick fibrous caps and
less inflammatory infiltrate. These features imply a
plaque that is less vulnerable to rupture and indicate
that fish oils may be important in establishing stability
of the plaque.
Inflammation
Inflammation has a central role in the development
and progression of coronary artery disease. Omega 3
Table 1 Effect of marine derived omega 3 fatty acids on death from coronary heart disease in secondary prevention of myocardial
infarction
Study Design Intervention
Intervention
events (%)
Control
events (%)
Absolute risk
reduction
(%)
Relative risk
reduction
(%)
No needed
to treat Comments
Diet and reinfarction
trial10
Randomised,
controlled, two year
follow up, 2033 men
after myocardial
infarction
Fish meal twice
weekly or fish oil
capsules if unable to
tolerate fish (1.5
g/d)
7.7* 11.4 3.7 32.5 27 Before routine use
of secondary
prevention treatment
such as aspirin, 
blockers, statins
Indian experiment of
infarct survival12
Randomised
double-blind placebo
controlled, one year
follow up, 360
patients after
myocardial infarction
Fish oil (EPA+DHA
1.8 g/d) or mustard
seed oil (ALA 2.9
g/d)
11.4* 22 10.6 48.2 10 Small size, high
mortality, may not
be applicable to
Western populations
GISSI-Prevenzione
trial, Italy11
Randomised,
controlled, 3.5 year
follow up, 11 324
patients after
myocardial infarction
Fish oil (EPA+DHA
0.85 g/d)
4.8** 6.8 2 29.7 50 Not blinded, no
placebo
Nilsen et al13 Randomised
double-blind placebo
controlled, 1.5 year
follow up, 300
patients after
myocardial infarction
Fish oil (EPA+DHA
3.5 g/d)
5.3 5.3 — — — Small size,
reasonable intake of
fish among general
population
*P<0.01 between control and intervention groups.
**P=0.024 between control and intervention groups.
EPA=eicosapentanoic acid, DHA=docosahexanoic acid, ALA= linolenic acid.
Box 1: Possible mechanisms of action of omega
3 fatty acids
• Antiarrhythmic
• Antithrombotic
• Antiatherosclerotic
• Anti-inflammatory
• Improves endothelial function
• Lowers blood pressure
• Lowers triglyceride concentrations
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fatty acids have recognised anti-inflammatory actions
that may contribute to their beneficial cardiac effects.
Omega 6 fatty acids can be converted into arachidonic
acid and then metabolised into the omega 6
eicosanoids (fig 4).20 These cellular mediators enhance
platelet aggregation and are generally pro-
inflammatory. Consumption of omega 3 fatty acids
increases eicosapentanoic acid in the cell membrane.
This competes with arachidonic acid for enzymatic
conversion into its own metabolites, the omega 3
derived eicosanoids. These are less active and can
partly oppose or antagonise the pro-inflammatory
actions of the omega 6 eicosanoids.
Independent of the effects on the metabolism of
eicosanoids fish oils suppress pro-inflammatory
cytokines and reduce expression of cell adhesion mol-
ecules.21 These are critical in recruiting circulating leu-
cocytes to the vascular endothelium, an important
event in the pathogenesis of atherosclerosis and
inflammation. These effects may be mediated through
actions on intracellular signalling pathways, leading to
reduced activation of transcription factors such as
NF-B.21 However, the precise effects of omega 3 fatty
acids on these fundamental cellular processes and their
potential impact on coronary heart disease are yet to
be delineated completely.
Endothelial function
Abnormal endothelial function is found in individuals
with cardiovascular risk factors or established coronary
heart disease. Omega 3 fatty acids have direct effects
on endothelial vasomotor function. Higher concentra-
tions are associated with improved dilation of the
brachial artery in young adults with cardiovascular risk
factors, which implies a protective effect on endothelial
function.w7 In hyperlipidaemic men omega 3 fatty acid
supplementation improved systemic arterial compli-
ancew8 and supplementation with docosahexanoic
acid increased vasodilator responses in the human
forearm.w9
Blood pressure
Fish oils can produce modest reductions in blood
pressure, possibly through their effects on endothelial
function discussed above. A recent meta-analysis of 36
randomised trials found a reduction in systolic blood
pressure of 2.1 mmHg and in diastolic blood pressure
of 1.6 mm Hg.22 However, most trials used relatively
high doses of fish oils (3.6 g/day), and the effects of
lower intakes of omega 3 fatty acids, such as those in
the secondary prevention trials, remain to be
established.
Triglyceride lowering
Omega 3 fatty acids reduce triglyceride concentra-
tions in a dose dependent manner, with intakes of
about 4 g per day lowering serum triglycerides by
25-30%.w10 Their effect on cholesterol is small and of
uncertain clinical importance. Higher doses (3-5
g/day) can be used in the treatment of hypertriglyceri-
Box 2: Recommendations for intake of omega 3
fatty acid
• Patients without documented coronary heart
disease: Eat a variety of (preferably oily) fish at least
twice weekly. Include oils and foods rich in  linolenic
acid
• Patients with documented coronary heart disease:
Consume 1 g of eicosapentanoic and docosahexanoic
acid daily, preferably from oily fish. Supplements could
be considered in consultation with a doctor
• Patients with hypertriglyceridaemia: Take 2-4 g of
eicosapentanoic acid and docosahexanoic acid daily,
provided as capsules under a doctor’s care
These are the recommendations of the American
Heart Association.23
Omega 6 Omega 3
Linoleic acid
Arachidonic acid Eicosapentanoic acid
Omega 6 derived eicosanoids Omega 3 derived eicosanoids
2 series prostanoids
TXA2,PGE2,PGI2
4 series leukotrienes
LTB4,LTC4-LTE4
Cyclo-oxygenase
Lipoxygenase
α linolenic acid
3 series prostanoids
TXA3,PGE3,PGI3
5 series leukotrienes
LTB5,LTC5-LTE5
Pro-inflammatory Anti-inflammatory
Fig 4 Synthesis of eicosanoids from omega 6 and omega 3 fatty acids. Arachidonic acid and
eicosapentanoic acid compete for the cyclo-oxygenase and lipoxygenase enzymes for
conversion into eicosanoids. Those derived from arachidonic acid are pro-inflammatory and
pro-aggregatory, whereas those derived from omega 3 fatty acids are anti-inflammatory and
inhibit platelet aggregation
Box 3: Consumption and sources of marine
derived omega 3 fatty acids
• Current consumption of marine derived omega 3
fatty acids is low, at 0.1-0.2 g/day. An expert US panel
of nutrition scientists has recommended an intake of
0.65 g/day whereas the British Nutrition Foundation’s
recommendation is 1.2 g/day.2 Secondary prevention
trials after myocardial infarction indicate that
consumption of 0.5-1.8 g/day of eicosapentanoic and
docosahexanoic acid from fish or fish oil supplements
may be beneficial. Intake of marine derived omega 3
fatty acids can be increased through diet or with fish
oil supplements. Oily fish such as mackerel, herring,
tuna, salmon, sardines and trout are rich sources of
eicosapentanoic and docosahexanoic acid (table 2),
and two to three servings per week should provide
approximately 1 g/day omega 3 fatty acids. Lean fish
such as cod or haddock have smaller amounts, and
fried fish (for example, from fast food establishments
or frozen products) contains minimal amounts of
omega 3 fatty acids.
• Concerns about the depletion of fish stocks will
become more pressing if the benefits of fish oils are
confirmed beyond the population after myocardial
infarction, as this may result in an unsustainable
increase in demand. Alternative strategies to increase
omega 3 intake include supplementing animal feed
with fish oil to augment the omega 3 content of eggs,
meat, and milk.2 Available foods can also be enriched
in eicosapentanoic and docosahexanoic acid, although
they may impart a fishy aroma or flavour. A different
approach independent of an adequate supply of fish
oil would involve using modern biotechnology to
genetically modify certain plants species, thereby
producing plants and plant oils rich in
eicosapentanoic and docosahexanoic acid.2
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daemia. Only a small reduction in triglycerides
occurred at the lower doses used in the GISSI-
Prevenzione trial11 (about 1 g/day), and it therefore
seems unlikely that this effect alone could be responsi-
ble for the cardiovascular benefits.
Clinical implications
Omega 3 fatty acids from fish or fish oil supplements
should be considered in the secondary prevention regi-
men of patients after myocardial infarction. Patients
should consume about 1 g/day of eicosapentanoic acid
and docosahexanoic acid, preferably by increasing their
intake of oily fish to at least two servings per week. Fish
oil capsules may be considered for those unable to toler-
ate fish or change their diet effectively. Approved
pharmaceutical grade capsules should be prescribed
rather than encouraging over the counter supplements.
Recent guidelines from the American Heart
Association (box 2) have gone further, supporting the
use of fish oil supplements for patients with
“documented” coronary heart disease.23 However, we
believe that more evidence is required before consider-
ing fish oil supplements for patients with coronary
heart disease outside the specific indication of myocar-
dial infarction. Others have argued that fish oil supple-
ments should not be recommended routinely for
patients after myocardial infarction until more
definitive evidence is available.w11
No trial has assessed the effects of fish oils on risk
of coronary heart disease in primary prevention, and
therefore explicit recommendations for this group
cannot be made currently. Such a trial may prove
impractical in terms of the numbers required.
However, on the basis of evidence from epidemiologi-
cal and observational studies the consumption of
(preferably oily) fish at least twice weekly should be
encouraged as part of a balanced diet. Box 3 and table
2 show current consumption and dietary sources of
eicosapentanoic and docosahexanoic acid.
Any recommendations regarding fish and fish oils
should be balanced against safety issues. Side effects
such as fishy aftertaste are uncommon, and gastro-
intestinal upset is infrequent at moderate intakes.23
Some reports show that fish oil may worsen glycaemic
control in diabetes, but two meta-analyses found no
adverse effect.w12 w13 Furthermore, a recent prospective
cohort study found that a higher consumption of
omega 3 fatty acids was associated with a lower
incidence of coronary heart disease and mortality in
diabetic women.w14 Concerns have been raised regard-
ing adverse effects on low density lipoprotein (LDL)
cholesterol and oxidative stress, but increases in LDL
cholesterol are modest and studies into oxidative
stress have been contradictory.w15 Overall these effects
are unlikely to be dominant given the apparent
cardiac benefits of omega 3 fatty acids. More specific
concerns regarding dietary fish relate to environmen-
tal contaminants, and a recent study showed that mer-
cury in fish may attenuate their cardioprotective
effects.24 Contaminants accumulate in larger, preda-
tory fish, and consumption of a variety of fish should
minimise any possible adverse effects.23
Future directions
Despite advances in our understanding of the cardio-
protective effects of fish oils in the past three decades,
many issues remain unresolved. A double blind,
placebo controlled trial of fish oil capsules in patients
after myocardial infarction is required, and further
trials are needed in individuals with risk factors for
coronary heart disease or with heart failure. The spe-
cific effects of eicosapentanoic acid versus docosa-
hexanoic acid on risk of coronary heart disease and
the relative merits of oily fish compared with fish oil
Table 2 Content of omega 3 fatty acids of selected fish and
seafood (adapted from the guidelines of the American Heart
Association23)
EPA+DHA content (g)
per 100 g serving of
fish (edible portion)
Amount of fish (in g)
required to provide 1 g
EPA+DHA
Tuna (fresh) 0.28-1.51 66-357
Atlantic salmon 1.28-2.15 42.5-70.9
Mackerel 0.4-1.85 54-250
Atlantic herring 2.01 50
Rainbow trout 1.15 87
Sardines 1.15-2 50-87
Halibut 0.47-1.18 85-213
Tuna (canned) 0.31 323
Cod 0.28 357
Haddock 0.24 417
Catfish 0.18 556
Flounder or sole 0.49 204
Oyster 0.44 227
Shrimp 0.32 313
Scallop 0.2 500
Cod liver oil capsule 0.19 5
Omacor (Pronova) 0.85 1
EPA=eicosapentanoic acid, DHA=docosahexanoic acid.
Omega 3 content varies markedly depending on species, season, diet, and
packaging and cooking methods, and the figures above are therefore rough
estimates.
Additional educational resources
Websites
www.nal.usda.gov/fnic/foodcomp/—USDA Nutrient Data Laboratory,
a database with online search function to find the omega 3 content of
various foods
www.foodstandards.gov.uk/multimedia/pdfs/fsis40_2003.pdf—Food
Standards Agency UK, provides data on mercury content of various fish
and advice on safe consumption for pregnant women and women of
childbearing potential.
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capsules also require further investigation. In addition
to trials with clinical end points, research efforts
should be focused on understanding the mechanisms
by which fish oils might confer cardiac benefits. This
will allow us not only to refine the clinical applications
of fish oils but hopefully also to identify other
therapeutic targets and help guide the development of
future treatments for coronary heart disease.
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Corrections and clarifications
Editor’s Choice and the filler “An extreme failure of concordance”
In his Editor’s Choice of 11 October, Richard Smith wrote about the
failure of communication between a Hmong family in California with a
daughter with severe epilepsy and the Californian healthcare system—as
described in a book from which we published an extract in the same
issue (as a “filler,” p 867). Unfortunately, Smith said that Lia had now
died. He was wrong to say this; she is still alive. Anne Fadiman, the
author of the book (The Spirit Catches You and You Fall Down) has asked
us to make clear that “Lia suffered profound neurological damage after
an episode of status epilepticus and that the parents thought that the
doctors and their drugs had injured her rather than helped.” In the filler,
we also misspelt the first name of the book’s author and introduced a
rogue apostrophe into the word “fractions.” We apologise for these
errors to all concerned.
Communicating risks at the population level: application of population impact
numbers
Richard F Heller and colleagues have reported an error in their
Education and Debate article (15 November, pp 1162-5) that was due to
a little recognised problem in calculating population attributable risk for
multiple levels of exposure. This led to an overestimation of population
attributable risk in table 2, which shows the impact of blood cholesterol
concentration on premature death from coronary heart disease (p
1164). However, this does not alter the general conclusion drawn from
the table (that the population impact of cholesterol concentrations of
5.2-6.5 mmol/l and of 6.5-7.8 mmol/l is larger than that of
concentrations above 7.8 mmol/l) or the substance of the article. Full
details of the correct calculations and the corrected table 2 appear on
bmj.com (http://bmj.bmjjournals.com/cgi/content/full/327/7424/
1162/DC1).
Submitting articles to the BMJ
We are now inviting all authors who want to submit a paper to
the BMJ to do so via the web (http://submit.bmj.com).
Benchpress is a website where authors deposit their
manuscripts and editors go to read them and record their
decisions. Reviewers’ details are also held on the system, and
when asked to review a paper reviewers will be invited to access
the site to see the relevant paper. The system is secure, protected
by passwords, so that authors see only their own papers and
reviewers see only those they are meant to.
Anyone with an internet connection and a web browser can use
the system.
The system provides all our guidance and forms and allows
authors to suggest reviewers for their paper. Authors get an
immediate acknowledgement that their submission has been
received, and they can watch the progress of their manuscript.
The record of their submission, including editors’ and reviewers’
reports, remains on the system for future reference.
The system itself offers extensive help, and the BMJ ’s editorial
office will help authors and reviewers if they get stuck.
Benchpress is accessed via http://submit.bmj.com or via a link
from bmj.com
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